QGQianqian Guo

Qianqian Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qianqian Guo has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Kejun Nan

    2 shared publications
  • Lili Jiang

    Phase I Clinical Trial Ward, The Second Affiliated Hospital of Xi’an, Jiaotong University, Xi’an, China

    2 shared publications
  • Tinghua Hu

    Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

    2 shared publications
  • Xuan Liang

    Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, People’s Republic of China

    2 shared publications
  • Yu Yao

    Department of Oncology, The First Affiliated Hospital, College of Medicine of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China

    2 shared publications
  • Allaka Nagalakshmi

    Department of Human Anatomy and Histology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 8/2 Trubetskaya Str., Moscow, 119991, Russia; Saveetha Institute of Basic Medical Sciences (SIBMS), Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India; Department of Molecular Diagnostics and Vaccines, SYENICA Biotech Limited, Chennai (Madras), Tamil Nadu, 602105, India

    1 shared publication

Latest Publications

  • Sex-specific divergence in global urological cancer trajectories to 2050: A dual-model projection analysis based on GLOBOCAN and GBD databases

    by Qianqian Guo, Lianghui Li, Narasimha M. Beeraka, Yi Zhang, Ruixiang Xu, Xiaojing Cui, Vladimir N. Nikolenko, Junqi Liu

  • Open Access

    Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients

    by Huixian Zhang, Xingya Li, Ziheng Mm Zhang, Siyuan Huang, Qianqian Guo, Ningning Yan

    As a second-generation selective oral anaplastic lymphoma kinase inhibitor, ceritinib is an effective first-line treatment for c-ros oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC). Its efficacy and safety for the treatment of crizotinib-resistant ROS1-rearranged NSCLC were explored in the study. A retrospective single-center study was conducted to investigate the efficacy of ceritinib in crizotinib-resistant ROS1-rearranged NSCLC. The objective response rate was the primary objective, while the disease control rate, progression-free survival and adverse events were secondary objectives. From December 2015 to October 2021, a total of 246 patients with ROS1-rearranged NSCLC were screened, 12 (4.9%) of whom were treated with ceritinib after the development of crizotinib resistance. Among the 12 crizotinib-resistant patients included, 3 displayed the efficacy of partial response and 3 had the efficacy of stable condition. The objective response rate, disease control rate and median progression-free survival of all patients were 25% (95% confidence interval [CI]: −3.7% to 53.7%; 3 of 12 patients), 50% (95% CI: 16.8% to 83.2%; 6 of 12 patients), and 10.5 months (95% CI, 5.7 to 15.3 months), respectively. In addition, of the 6 patients with brain metastases, an intracranial disease control rate of 66.7% (95% CI:12.5% to 120.9%) was obtained. The research results reveal that ceritinib can be a treatment option for ROS1-rearranged NSCLC patients after the development of crizotinib resistance.


  • Open Access

    High expression of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) predicted poor prognosis in Glioblastoma multiforme

    by Ke Ma, Yanxin Li, Xianwei Zhang, Qianqian Guo

    Purpose: Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) played an important role in inflammatory reactions. Recently the roles of TREM-1 in cancer had been explored, but not in Glioblastoma multiforme (GBM). The study was performed to explore the significance of TREM-1 in GBM. Methods: Immunohistochemical staining of TREM-1 was performed in 91 operative patients diagnosed with GBM. Clinicopathological characteristics and survival time were recorded. Besides, TREM-1 expression and its effect on prognosis were analyzed using online GEPIA, TCGA and CGGA databases. Then the expressionprofile of TCGA-GBM cohort was used to perform functional enrichment analysis. CIBERSORT method and TIMER database were used to estimate the tumor-infiltrating immune cells (TIICs). ESTIMATE algorithm was used to estimate the immune-stromal score. Lastly, the relationships between TREM-1 and TIICs, immune-stromal score and immune checkpoint genes (ICGs) were analyzed. Results: The expression of TREM-1 was up-regulated in GBM and high TREM-1 expression predicted poor prognosis. TREM-1, IDH1, surgical resection, postoperative radiotherapy and temozolomide chemotherapy were associated with the survival time of GBM patients, but only surgical resection and TREM-1 expression were independent prognostic factors. GBM with high TREM-1 expression exhibited more infiltrate of neutrophils and macrophage. TREM-1 was positively associated with immune-stromal score and multiple ICGs, most of whom were involved in immunosuppressive responses. Conclusions: The study revealed high expression of TREM-1in GBM was an independent poor prognosis factor and TREM-1 was associated with the immunosuppressive microenvironment. Blocking TREM-1, or combing block TREM-1 and ICGs may be a strategy for enhancing GBM immune response.

  • Open Access

    In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines

    by Min-Cong Wang, Xuan Liang, Zhi-Yan Liu, Jie Cui, Ying Liu, Li Jing, Li-Li Jiang, Jie-Qun Ma, Li-Li Han, Qian-Qian Guo, et al.

    The concurrent administration of chemotherapy and epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) has previously produced a negative interaction and failed to confer a survival benefit to non‑small cell lung cancer (NSCLC) patients compared with first‑line cytotoxic chemotherapy. The present study aimed to investigate the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib in NSCLC cell lines and clarify the underlying mechanisms. HCC827, H1975, H1299 and A549 human NSCLC cell lines with wild‑type and mutant EGFR genes were used as in vitro models to define the differential effects of various schedules of cisplatin/paclitaxel with icotinib treatments on cell growth, proliferation, cell cycle distribution, apoptosis, and EGFR signaling pathway. Sequence‑dependent antiproliferative effects differed among the four NSCLC cell lines, and were not associated with EGFR mutation, constitutive expression levels of EGFR or downstream signaling molecules. The antiproliferative effect of cisplatin plus paclitaxel followed by icotinib was superior to that of cisplatin or paclitaxel followed by icotinib in the HCC827, H1975, H1299 and A549 cell lines, and induced more cell apoptosis and G0/G1 phase arrest. Cisplatin and paclitaxel significantly increased the expression of EGFR phosphorylation in the HCC827 cell line. However, only paclitaxel increased the expression of EGFR phosphorylation in the H1975 cell line. Cisplatin/paclitaxel followed by icotinib influenced the expression of p‑EGFR and p‑AKT, although the expression of p‑ERK1/2 remained unchanged. The results suggest that the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib differed among the NSCLC cell lines. The results also provide molecular evidence to support clinical treatment strategies for NSCLC patients.


    • 1 May 2014
      • Vol. 34  (5) , 627-30

    [Starvation-induced autophagy in cultured non-small cell lung cancer cells].

    by Qianqian Guo, Zhiyan Liu, Lili Jiang, Tinghua Hu, DongFan Li, Ying Liu, Mengjie Liu, Xuan Liang, Kejun Nan

    To observe autophagy induced by starvation in non-small cell lung cancer A459 and 95D cells. A549 and 95D cells in logarithmic growth in 1640 medium were cultured in Earle's balanced salt solution (EBSS) for 0, 1, 2, 3, 4 or 5 h. Autophagosome formation in the cell culture was observed by MDC fluorescent staining, and the expression of microtubule-associated protein 1 light chain 3 (LC3) and Beclin1 in the cells were detected using Western blotting. Compared with the control cells, the cells with prolonged starvation showed increased MDC-positive cells and autophagosome formation. The expression of Beclin-1 and the LC3-II/LC3-I ratio also increased as the starvation prolonged, reaching the peak levels at 3 h and 4 h, respectively. Autophagy can be induced by starvation in A549 and 95D cells in correlation with the expression of autophagy-related proteins LC3 and Beclin-1. These cell models of nutritional deficiency-induced autophagy may allow for a better understanding of the role of autophagy in the development of non-small cell lung cancer.


    • 1 February 2014
      • Vol. 34  (2) , 153-8

    [CXCR4 and Nrf2 expressions in non-small cell lung cancer and their clinical implications].

    by Tinghua Hu, Yu Yao, Shuo Yu, Hui Guo, Tao Tian, Lili Han, Wenjuan Wang, Qianqian Guo, Jing Wang, Kejun Nan, et al.

    To detect the expressions of CXCR4 and Nrf2 in non-small cell lung cancer (NSCLC) tissues and analyze their association with the clinicopathological features of NSCLC. We investigated the expressions of CXCR4 and Nrf2 in 66 NSCLC and corresponding distant normal tissue specimens using immunohistochemistry and real-time PCR. The expressions of CXCR4 protein and mRNA were significantly higher in NSCLC tissue specimens than in the distant normal tissues, while the expression of Nrf2 protein and mRNA increased significantly in NSCLC tissues compared to those in the distant normal tissues (P<0.01). A high expression level of CXCR4 was positively correlated with a large tumor size (P=0.048), poor differentiation (P=0.024), advanced TNM stage (P=0.018), lymph node metastasis (P=0.004), and distant metastasis (P=0.016). The expression of Nrf2 protein was positively correlated with a large tumor size (P=0.008), advanced TNM stage (P=0.028), lymph node metastasis (P=0.038), and distant metastasis (P=0.023). A strong correlation was found between CXCR4 and Nrf2 expressions in NSCLC tissues (r=0.324, P<0.01), and the co-expression of CXCR4 and Nrf2 was strongly correlated with lymph node metastasis and distant metastasis. Abnormal expressions of CXCR4 and Nrf2 may contribute to the progression and malignant biological behavior of NSCLC.